Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Pathologic Complete Response × sargramostim × 30 days × Clear all

Sponsor

Conditions

Neuroblastoma 4 Triple Negative Breast Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Ganglioneuroblastoma 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Neoplasm Metastasis 1 Gliosarcoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Carcinosarcoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 2 durvalumab 2 Standard of Care 2 Paclitaxel 2 Oxaliplatin 2 Irinotecan 2 Chemoradiotherapy 2 Carboplatin 2 Capecitabine 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 talazoparib 1 sarilumab 1 relugolix 1 regorafenib 1 pexidartinib 1 pertuzumab 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 enzalutamide 1 dostarlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡